The incidence of sexually transmitted diseases (STDs) continues to rise at an alarming rate. Currently 5 of the 10 most commonly reported infectious diseases in the United States are sexually transmitted, and an estimated 12 million cases of STDs occur annually [1] . Topical microbicides, which are applied directly to the genital tract on an episodic basis and protect against infection, are an attractive approach to reducing the spread of STDs. The fact that microbicide use can be female initiated (if necessary, without partner consent) has added impetus to the search for safe and effective compounds, because it is recognized that females bear a disproportionate burden of STD infection and are frequently unable to negotiate condom use [1] [2] [3] . To date there have been two main approaches to the development of topical microbicides. The first has been to identify detergents or surface active agents that inactivate STD pathogens by disruption of the outer envelope or membrane. The compound that has been most fully evaluated in this regard is the detergent nonoxynol-9 (N-9), which is the active ingredient in many over-the-counter spermicides [4] [5] [6] .
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The second strategy has been to identify compounds that can prevent infection by blocking binding of the pathogen to host cells. The naphthalene sulfonate polymer PRO 2000 (Procept, Cambridge, MA) is an example of this second approach. PRO 2000 was originally found to disrupt early molecular events in the human immunodeficiency virus (HIV) type 1 infection process and to suppress infection by a broad range of HIV isolates [7] . More recent studies have shown that the compound is also active in vitro against two other common STD pathogens: herpes simplex virus type 2 (HSV-2; 50% effective concentration mg/mL) and Chlamydia trachomatis (EC 50 0.6 mg/ [EC ] ! 0.03 50 mL) [8] . Thus, it has the potential to act as a broad-spectrum microbicide. In addition, PRO 2000 has a number of other characteristics that are desirable in a microbicide. It is straightforward to synthesize, highly water soluble and stable, virtually colorless and odorless, and compatible with latex condoms. Furthermore, two recent phase 1 clinical trials showed that vaginal gel formulations containing р4% of PRO 2000 are safe and well tolerated (unpublished data).
In the studies reported here, we examined the ability of PRO 2000 both in solution and in the vaginal gel formulations used in recent clinical trials to act as a topical microbicide against HSV-2 infection in vivo in a mouse model of genital herpes. land, OH), respectively, 0.05% lactic acid, and trolamine (to pH 4.5). A placebo gel of comparable viscosity was prepared by use of 1.0% (wt/wt) Carbopol 1382. The powder and gel formulations were supplied by Procept.
Materials and Methods
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Viruses and cells. HSV-2 strain 186 [9] was prepared by culture in low-passage primary rabbit kidney (RK) cells. Virus stocks were maintained frozen (Ϫ80ЊC). RK cells were prepared as previously described [10] and maintained in Eagle's basal medium supplemented with 10% (vol/vol) fetal bovine serum.
Mouse model of genital HSV-2 infection. Female Swiss Webster mice weighing 18-21 g (Harlan, Indianapolis) were administered 0.1 mL of a suspension containing 3 mg of medroxyprogesterone acetate (Upjohn Pharmacia, Kalamazoo, MI) by subcutaneous injection in the shoulder region 7 and 1 days prior to viral challenge, to increase susceptibility to vaginal HSV infection. On the day of viral challenge, animals were anesthetized by intraperitoneal injection of 0.25 mL of a solution containing 6.5 mg/mL sodium pentobarbital. The vaginal vault was swabbed twice, first with a moistened type 1 calcium alginate-tipped swab (Fisher Scientific, Pittsburgh) and then with a dry swab. Animals were then inoculated by instillation of 15 mL of a suspension containing 4.0 log 10 pfu of HSV-2 186.
Vaginal swab samples were collected from all animals on day 2 after inoculation and stored frozen (Ϫ80ЊC) until assayed for the presence of virus by culture on susceptible RK cell monolayers. Mice were evaluated daily, to day 21 after inoculation, for evidence of symptomatic infection that included hair loss and erythema around the perineum, chronic urinary incontinence, hind-limb paralysis, and mortality. For the purpose of these studies, animals that did not develop symptoms were defined as infected if virus was isolated from vaginal swab samples collected on day 2 after inoculation.
Statistics. Incidence data were compared by Fisher's exact test. All comparisons were two-tailed.
Results
In the initial study (table 1; . Subsequently, all but 1 of these mice developed symptoms and died, demonstrating that the placebo gel provided no protection against viral challenge. In contrast, PRO 2000, both in solution in PBS and in the 4% gel formulation, provided significant protection against disease and infection, compared with the appropriate control group ( each). All 3 PRO P ! .001 2000-treated animals that became infected were in the group that received the 10% PRO 2000 solution. Consequently, we chose to use the gel formulation in subsequent studies, to further evaluate PRO 2000 as a topical microbicide. In a second study (table 1; series 2), animals treated with the 4% gel 20 s before viral challenge were completely protected. In addition, treatment with a lower dose (0.5%) PRO 2000 gel was also effective, providing substantial but not complete protection against both disease and infection, compared with the placebo gel ( each).
We next examined the effect of the time of application on efficacy. Table 2 shows that mice treated with the 4% PRO 2000 gel 5 min before viral challenge were completely protected against infection. When the gel was administered 15 min before challenge, 11 of 12 mice were protected, and even when the gel was applied 60 min before challenge we observed both significant protection against infection ( ) and development of P ! .01 disease (
). P ! .05
Discussion
An effective microbicide must be both highly protective and safe even when administered one or more times daily. This safety requirement has led to concerns that frequent application of microbicides containing surface-active agents at concentrations sufficient to inactivate pathogens might also cause damage to the vaginal epithelium and thus, under certain circumstances, actually increase susceptibility to STD infection. Clinical studies with N-9 appear to confirm these concerns, since there is substantial evidence that frequent use can cause inflammation and disruption of the vaginal and cervical epithelium [11, 12] . In addition, while N-9 protected against a number of STD pathogens in animal studies [13, 14] , results from clinical trials have been contradictory [4] [5] [6] . Thus, there is considerable interest both in the identification of novel compounds with potential as topical microbicides [14] [15] [16] and in the development of microbicides, such as PRO 2000, that act by blocking infection rather than by the destruction of the pathogen. It is hoped that such agents, in addition to being highly protective, will not cause cytotoxicity even after frequent use. The results of two recent phase 1 clinical trials provide preliminary evidence that vaginal gels containing р4% PRO 2000 are both safe and well tolerated (unpublished data). The results reported here provide the first evidence that PRO 2000 can provide in vivo protection against a recognized STD pathogen, HSV-2.
We show that a single prophylactic application of PRO 2000, either in solution or formulated in a vaginal gel at concentrations used in phase 1 clinical trials, is sufficient to provide significant protection against HSV-2 infection in a mouse model. The 4% vaginal gel formulation was 100% protective when administered shortly before viral challenge and retained good efficacy for at least 60 min. This ability to be effective quickly after application and to maintain protective efficacy for an extended period in the genital tract is an important characteristic for a microbicide, since it is likely that there will be considerable variations between the time of application and exposure to an STD pathogen. On the basis of the observed in vivo effectiveness of PRO 2000 against genital HSV-2 infection, further studies of PRO 2000's potential as a microbicide are warranted.
